Medlive Technology Co (HKSE:02192) YoY Rev. per Sh. Growth : 28.52% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Medlive Technology Co YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Medlive Technology Co's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 was 28.52%.

Medlive Technology Co's Revenue per Share for the six months ended in Dec. 2023 was HK$0.36.

Medlive Technology Co YoY Rev. per Sh. Growth Historical Data

The historical data trend for Medlive Technology Co's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlive Technology Co YoY Rev. per Sh. Growth Chart

Medlive Technology Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY Rev. per Sh. Growth

Get a 7-Day Free Trial

43.07

87.24

49.32

-13.14

28.78

Medlive Technology Co Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
YoY Rev. per Sh. Growth	Get a 7-Day Free Trial					23.36	-8.73	4.92	22.97	28.52

Medlive Technology Co YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Medlive Technology Co's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY Rev. per Sh. Growth (A: Dec. 2023 )
=	(Revenue per Share (A: Dec. 2023 )	-	Revenue per Share (A: Dec. 2022 ))	/	\| Revenue per Share (A: Dec. 2022 ) \|
=	(0.613	-	0.476)	/	\| 0.476 \|
=	28.78 %

Medlive Technology Co's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY Rev. per Sh. Growth (Q: Dec. 2023 )
=	(Revenue per Share (Q: Dec. 2023 )	-	Revenue per Share (Q: Dec. 2022 ))	/	\| Revenue per Share (Q: Dec. 2022 )) \|
=	(0.356	-	0.277)	/	\| 0.277 \|
=	28.52 %

Medlive Technology Co YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Medlive Technology Co's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Medlive Technology Co (HKSE:02192) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Medlive Technology Co Ltd (HKSE:02192) » Definitions » YoY Rev. per Sh. Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1 Baijialou Chaoyang North Road, E1 Red Manor International Bonded Innovation Park, Chaoyang District, Beijing, CHN

Website

https://www.medlive.cn

Medlive is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms to specifically target physicians through different promotional channels. The company uses in-house and third-party content teams to produce advertising for its clients by profiling the user preferences of the physicians on the platform who drive procurement and prescription decisions. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and SaaS solution that help with medical conferences and clinical research. M3, Japan's leading digital healthcare marketing company owns 38.8% of Medlive through a joint venture.

Executives

Fil Limited	2201 Interest of corporation controlled by you
Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
M3, Inc.	2101 Beneficial owner
Sony Group Corporation	2201 Interest of corporation controlled by you
Tian Liping
Zhang Xiaofeng	2101 Beneficial owner
Liu Lingdi	2101 Beneficial owner
Tian Lixin	2101 Beneficial owner
Brown Brothers Harriman & Co.	2502 Approved lending agent
Fidelity Funds	2101 Beneficial owner
Tiantian Co., Limited

Medlive Technology Co (HKSE:02192) Headlines

No Headlines